LOGIN  |  REGISTER
Cue Biopharma
Cue Biopharma

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

May 29, 2025 | Last Trade: US$21.73 0.11 0.51

SAN FRANCISCO, May 29, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced that management will participate in multiple upcoming healthcare conferences in June.

Jefferies Global Healthcare Conference

Format: Fireside chat and 1x1 meetings
Date/time: Thursday, June 5 at 8:10 a.m. ET
Location: New York, NY

Goldman Sachs Global Healthcare Conference

Format: Fireside chat and 1x1 meetings
Date/time: Wednesday, June 11 at 10:40 a.m. ET
Location: Miami, FL

The live and archived webcasts of the fireside chats will be accessible from the company’s website at https://ir.structuretx.com/events-presentations/events and a replay will be available for 90 days.

About Structure Therapeutics 

Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, Structure Therapeutics has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world. For additional information, please visit www.structuretx.com.

Investors:
Danielle Keatley
Structure Therapeutics Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media:
Dan Budwick
1AB
This email address is being protected from spambots. You need JavaScript enabled to view it.

Chimerix

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page